W
WAVEMAN · COMPANY
LYB · Lyondellbasell Industries N.V.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

LYB

LyondellBasell Industries N.V.
PHARMA & BIOTECH · INDUSTRIAL ORGANIC CHEMICALS · CIK 0001489393
CONGRESS · 2☆ WATCH
INSIDER NET · 180D
-$741.6K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
2
FUNDS ADDED · QTR
481
13F, latest reported quarter
REVENUE GROWTH
-9.7%
XBRL, annual
NET MARGIN
-2.4%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$741.6K over 180 days
below 58% of Pharma & Biotech
CONGRESS
2 members bought in the last year
more than 65% of Pharma & Biotech
FUNDS
481 funds added or opened last quarter
more than 96% of Pharma & Biotech
REVENUE
-9.7% year over year
below 70% of Pharma & Biotech
MARGIN
-2.4% net margin
more than 64% of Pharma & Biotech
BUYBACKS
$201.0M repurchased, FY to 2025-12-31
more than 77% of Pharma & Biotech
SHORT
3.8% of shares outstanding short · 2.7 days to cover · settled 2026-07-31
below 53% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
481 funds added or opened positions in the latest 13F quarter, of 886 holders.
2 members of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +19.7%
+19.7%12M
-24%+2%+28%+54%2025-092025-102025-122026-032026-052026-072026-09 2026-03-09 · Blavatnik Len sold $12.9M2026-03-09 · Blavatnik Len sold $7.9M2026-03-09 · Blavatnik Len sold $5.4M2026-05-13 · Kaplan Jeffrey A sold $741.6K2025-11-12 · Foley Kimberly A bought $246.6K2026-03-09 · Blavatnik Len sold $28.2K2026-03-09 · Blavatnik Len sold $17.3K2026-03-09 · Blavatnik Len sold $11.9K
INSIDER BUYINSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows a net $741.6K sold by insiders over 180 days, 481 funds added last quarter, 2 Congress member(s) bought in 12 months. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, LyondellBasell Industries N.V. insiders sold a net $741.6K of stock across 104 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Kaplan Jeffrey A
EVP, Chief PC, Leg & Corp Ofc
SELL
2026-05-13
10,000.0
$741.6K
Blavatnik Len
SELL
2026-03-09
189,277.0
$12.9M
Blavatnik Len
SELL
2026-03-09
177.0
$11.9K
Blavatnik Len
SELL
2026-03-09
80,679.0
$5.4M
Blavatnik Len
SELL
2026-03-09
251.0
$17.3K
104 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 99 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
29,298,859.0 sh
$1.5B
VANGUARD CAPITAL MANAGEMENT LLC
16,882,431.0 sh
$888.9M
STATE STREET CORP
14,734,948.0 sh
$775.8M
Capital World Investors
13,773,272.0 sh
$725.2M
VANGUARD PORTFOLIO MANAGEMENT LLC
11,984,747.0 sh
$631.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Invesco High Yield Equity Dividend AchieversTM ETF
$50.6M POSITION · AS OF 2026-04-30
4.7%
Invesco S&P 500 Equal Weight Materials ETF
$7.5M POSITION · AS OF 2026-04-30
4.2%
Invesco S&P 500 High Dividend Growers ETF
$392.7K POSITION · AS OF 2026-02-28
3.8%
PROFUND VP MATERIALS
$330.5K POSITION · AS OF 2026-03-31
2.6%
Applied Finance Dividend Fund
$733.0K POSITION · AS OF 2026-04-30
2.4%
ALPS Sector Dividend Dogs ETF
$32.6M POSITION · AS OF 2026-02-28
2.4%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$30.2B$33.4B$33.3B$50.5B
OPERATING INCOME$-420.0M$1.9B$2.7B$5.1B
NET INCOME$-738.0M$1.4B$2.1B$3.9B
EPS (DILUTED)-2.344.156.4611.81
OPERATING CASH FLOW$2.3B$3.8B$4.9B$6.1B
CASH$3.4B$3.4B$3.4B$2.2B
BUYBACKS$201.0M$195.0M$211.0M$420.0M
DIVIDENDS PAID$1.8B$1.7B$1.6B$3.2B
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →